When stopping GLP-1 drugs like Ozempic, hunger doesn't just return to normal; it comes back with a "ferocious, animalistic" vengeance that is far more intense than before starting the medication. This powerful rebound effect is a primary driver of rapid weight regain.

Research shows that while GLP-1 drug users eat less, they will pay more for high-quality ingredients. This creates a strategic opportunity for restaurants to increase profit margins by offering smaller, premium-priced dishes, tapping into the retail psychology that smaller items can carry a higher proportional markup.

Eli Lilly and Novo Nordisk's DTC programs for weight loss drugs give employers an alternative to point employees towards, providing cover to drop expensive insurance coverage and potentially reducing access for patients who rely on it.

Customers who pay a significant initiation fee are psychologically primed to stay longer to justify their initial investment, even if their monthly rate is lower. This "sunk cost fallacy" makes them a "stickier" customer than those on low-cost, no-commitment plans.

A surprising driver of the burgeoning global obesity drug market, projected to hit $20 billion outside the U.S., is that it's almost entirely cash-pay. Consumers in countries like the UK are willing to spend hundreds of dollars per month out-of-pocket, demonstrating strong demand independent of traditional reimbursement systems.

Despite showing massive weight loss, new obesity drugs from Eli Lilly and others have high discontinuation rates due to side effects. This suggests the industry's singular focus on efficacy may be hitting diminishing returns, opening a new competitive front based on better patient tolerance and adherence.

Treating obesity with drugs like Wegovy for a limited time, such as two years, is akin to only treating high cholesterol temporarily. This policy ignores the medical reality that obesity is a chronic disease requiring lifelong management, not a short-term condition.

A major problem with GLP-1 drugs is that users often regain weight after stopping because they haven't learned new habits. Nutrisense addresses this by providing data and coaching to build sustainable lifestyle changes, making it a complementary, long-term solution.

The obesity market is evolving beyond maximum weight loss. Key differentiators will become dosing convenience, side effect profiles, and preserving lean muscle. This creates space for novel mechanisms, potentially as add-on therapies to lower GLP-1 doses and mitigate side effects.